WJTOG 0105 demonstrated median survival of 20.5, 19.8 and 22.0 months with 5 year OS of 17.5%, 17.8% and 19.8%. There was no significant difference between the 3 arms.r
© J Clin Oncol 2010
In the Carter study the median overall survival for the maintenance arm was 16.1 months and 26.9 months for the observation arm. The median progression-free survival was 8.2 months for the maintenance arm and 10.2 months for the observation arm.r
A: Overall Survival; B: Progression Free Survival
Maintenance: weekly paclitaxel 70 mg/m2 x 3 weeks followed by 1 week of rest for 6 months.
Observation: observation for a 6-month period.
© Clin Lung Cancer 2012
The median survival time was 20.2 months in the PE arm and 13.5 months in the PC arm. The overall survival at 1,2,3 years respectively was 65.6%, 36.4%, 33.1% in the PE arm and 54.5%, 16.2%, 13% in the PC arm.
The progression-free survival at 1,2,3 years respectively was 46.9%, 21.9%, 21.9% in the PE arm and 42.4%, 13.6%, 10.2% in the PC arm.
As the overall survival and progression-free survival were significantly higher in the PE arm than the PC arm the PC weekly regimen is not recommended over the PE regimen according to this study.r
© Lung Cancer 2012